Your pathology report uses a word that puzzled you. Sarcomatoid. Or epithelioid. Or biphasic. The oncologist explained that this is the cell type, that it affects how aggressive the cancer is, and that it shapes treatment decisions. You did not catch all the implications.
This guide explains the three mesothelioma cell types in plain language. You will learn what each type looks like, what each means for treatment, what the prognosis differences are, and why the cell type might be the single most important feature in your pathology report.
Epithelioid Mesothelioma
Epithelioid is the most common cell type, accounting for roughly sixty to seventy percent of mesothelioma cases. Under the microscope, epithelioid mesothelioma cells appear relatively uniform, polygonal, and arranged in patterns that can resemble glandular tissue. The growth tends to be more orderly than the other cell types.
Epithelioid mesothelioma carries the most favourable prognosis among the three types. Median survival ranges from eighteen months to three or more years depending on stage and treatment. Patients with epithelioid disease are the strongest candidates for aggressive multimodal treatment including surgery. The response to chemotherapy and immunotherapy is generally better than for the other types.
Sarcomatoid Mesothelioma
Sarcomatoid is the least common cell type, accounting for ten to twenty percent of cases. Under the microscope, sarcomatoid cells are spindle-shaped, less differentiated, and grow in disorganised patterns. The biology is more aggressive than epithelioid disease.
Sarcomatoid mesothelioma has historically had the most challenging prognosis. Median survival is shorter, often six to twelve months, although immunotherapy combinations have improved outcomes recently. Patients with sarcomatoid disease have generally been considered poor surgical candidates because surgery alone has not produced strong outcomes. Chemotherapy response is more limited than for epithelioid disease.
The recent good news is that sarcomatoid mesothelioma seems to respond particularly well to immunotherapy. The CheckMate 743 trial showed that the survival benefit of nivolumab-ipilimumab compared to chemotherapy was largest in the sarcomatoid and biphasic subgroups. This has changed practice. Patients with sarcomatoid mesothelioma are now strongly considered for first-line immunotherapy.
Biphasic Mesothelioma
Biphasic mesothelioma combines features of both epithelioid and sarcomatoid cell types in the same tumour. Pathologists report the percentage of each component when documenting biphasic disease. The relative proportions affect prognosis. Tumours that are predominantly epithelioid behave more like epithelioid disease. Tumours that are predominantly sarcomatoid behave more like sarcomatoid disease.
Biphasic mesothelioma represents twenty to thirty percent of cases. The intermediate biology means the prognosis sits between the other two types, but the variation is large depending on cell-type proportions. Treatment selection takes the proportion into account.
Why the Cell Type Matters for Surgery Decisions
Surgical candidacy is heavily influenced by cell type. Epithelioid patients are routinely considered for surgical resection if other criteria are met. Sarcomatoid patients are usually not surgical candidates because surgery alone has not produced meaningful long-term survival in this group. Biphasic patients are evaluated case by case based on the cell-type proportions and other features.
This pattern reflects the underlying biology. Surgery removes localised disease but cannot address microscopic spread that occurs early in aggressive sarcomatoid tumours. For epithelioid disease, where the biology is more contained, surgery has a meaningful role.
Why the Cell Type Matters for Chemotherapy
Chemotherapy with cisplatin and pemetrexed produces meaningful responses in most epithelioid patients but smaller responses in sarcomatoid patients. The difference reflects the cellular biology and the speed of disease progression. Treatment plans for sarcomatoid patients have shifted toward immunotherapy as first-line therapy in many cases, with chemotherapy reserved or used in combination.
Why the Cell Type Matters for Immunotherapy
The pattern with immunotherapy reverses the historical disadvantage of sarcomatoid disease. The nivolumab-ipilimumab combination produces particularly strong responses in sarcomatoid and biphasic mesothelioma compared to chemotherapy. For these subgroups, immunotherapy first-line is now the preferred approach for unresectable disease.
For epithelioid mesothelioma, the choice between chemotherapy first or immunotherapy first is more nuanced. Both produce meaningful responses. Combination protocols using chemotherapy plus immunotherapy are being investigated to maximise response rates.
Why Second-Look Pathology Matters
Cell-type classification can be challenging, particularly for biphasic tumours where the proportions need to be carefully estimated and for sarcomatoid tumours that mimic other spindle-cell cancers. A second-look pathology review by a mesothelioma-experienced pathologist sometimes refines the classification or even changes the diagnosis.
If your cell type was initially classified ambiguously, or if the local pathologist sees few mesothelioma cases per year, ask whether second-look pathology at a specialty centre would be useful. The classification affects treatment decisions, and getting it right is worth the extra step.
Closing Note
Knowing your cell type is essential to understanding your treatment plan and prognosis. The numbers and survival statistics that apply to mesothelioma overall do not necessarily apply to your specific cell type. Ask your oncologist for the precise cell type and, in biphasic cases, the percentage of each component. Use this information to ask sharper questions about treatment decisions and expected response.
The cell type is not destiny. Treatment options exist for every cell type. The right plan for sarcomatoid disease looks different from the right plan for epithelioid disease, but both can produce meaningful survival when treatment is matched to biology.
This article is for educational purposes and does not replace personalised guidance from a treating oncologist or pathologist.